These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34497363)

  • 81. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma.
    Andrici J; Jung J; Sheen A; D'Urso L; Sioson L; Pickett J; Parkhill TR; Verdonk B; Wardell KL; Singh A; Clarkson A; Watson N; Toon CW; Gill AJ
    Hum Pathol; 2016 May; 51():9-15. PubMed ID: 27067777
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.
    Pillappa R; Maleszewski JJ; Sukov WR; Bedroske PP; Greipp PT; Boland JM; Yi ES; Peikert T; Aubry MC; Roden AC
    Am J Surg Pathol; 2018 Feb; 42(2):256-263. PubMed ID: 29076876
    [TBL] [Abstract][Full Text] [Related]  

  • 83. p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma.
    Hwang H; Tse C; Rodriguez S; Gown A; Churg A
    Am J Surg Pathol; 2014 May; 38(5):681-8. PubMed ID: 24503757
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma.
    Chiu K; Lee L; Cheung S; Churg AM
    Mod Pathol; 2018 Sep; 31(9):1400-1403. PubMed ID: 29785020
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Expression of snail, twist, and Zeb1 in malignant mesothelioma.
    Merikallio H; Pääkkö P; Salmenkivi K; Kinnula V; Harju T; Soini Y
    APMIS; 2013 Jan; 121(1):1-10. PubMed ID: 23030626
    [TBL] [Abstract][Full Text] [Related]  

  • 86. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
    Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N
    Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
    [TBL] [Abstract][Full Text] [Related]  

  • 87. β-catenin expression in benign and malignant pleural disorders.
    Anani W; Bruggeman R; Zander DS
    Int J Clin Exp Pathol; 2011; 4(8):742-7. PubMed ID: 22135721
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The immunohistochemical profile of malignant mesotheliomas of the tunica vaginalis: a study of 20 cases.
    Winstanley AM; Landon G; Berney D; Minhas S; Fisher C; Parkinson MC
    Am J Surg Pathol; 2006 Jan; 30(1):1-6. PubMed ID: 16330935
    [TBL] [Abstract][Full Text] [Related]  

  • 89. BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.
    Erber R; Warth A; Muley T; Hartmann A; Herpel E; Agaimy A
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):67-73. PubMed ID: 30640754
    [TBL] [Abstract][Full Text] [Related]  

  • 90. L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray.
    Kettunen E; Nicholson AG; Nagy B; Wikman H; Seppänen JK; Stjernvall T; Ollikainen T; Kinnula V; Nordling S; Hollmén J; Anttila S; Knuutila S
    Carcinogenesis; 2005 Jan; 26(1):17-25. PubMed ID: 15447976
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma.
    Sington JD; Morris LS; Nicholson AG; Coleman N
    Histopathology; 2003 May; 42(5):498-502. PubMed ID: 12713628
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Epithelial-mesenchymal transition in malignant mesothelioma.
    Fassina A; Cappellesso R; Guzzardo V; Dalla Via L; Piccolo S; Ventura L; Fassan M
    Mod Pathol; 2012 Jan; 25(1):86-99. PubMed ID: 21983934
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas.
    Cote RJ; Jhanwar SC; Novick S; Pellicer A
    Cancer Res; 1991 Oct; 51(19):5410-6. PubMed ID: 1913660
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status.
    Tessier-Cloutier B; Kortekaas KE; Thompson E; Pors J; Chen J; Ho J; Prentice LM; McConechy MK; Chow C; Proctor L; McAlpine JN; Huntsman DG; Gilks CB; Bosse T; Hoang LN
    Mod Pathol; 2020 Aug; 33(8):1595-1605. PubMed ID: 32203095
    [TBL] [Abstract][Full Text] [Related]  

  • 95. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
    Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
    [TBL] [Abstract][Full Text] [Related]  

  • 96. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma.
    Chapel DB; Schulte JJ; Berg K; Churg A; Dacic S; Fitzpatrick C; Galateau-Salle F; Hiroshima K; Krausz T; Le Stang N; McGregor S; Nabeshima K; Husain AN
    Mod Pathol; 2020 Feb; 33(2):245-254. PubMed ID: 31231127
    [TBL] [Abstract][Full Text] [Related]  

  • 97. My approach to the diagnosis of mesothelial lesions.
    Butnor KJ
    J Clin Pathol; 2006 Jun; 59(6):564-74. PubMed ID: 16731600
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Calretinin: a novel immunocytochemical marker for mesothelioma.
    Doglioni C; Dei Tos AP; Laurino L; Iuzzolino P; Chiarelli C; Celio MR; Viale G
    Am J Surg Pathol; 1996 Sep; 20(9):1037-46. PubMed ID: 8764740
    [TBL] [Abstract][Full Text] [Related]  

  • 99. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma.
    Ordóñez NG
    Hum Pathol; 2005 Apr; 36(4):372-80. PubMed ID: 15891998
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Guidelines for Pathologic Diagnosis of Mesothelioma.
    Husain AN; Chapel DB; Attanoos R; Beasley MB; Brcic L; Butnor K; Chirieac LR; Churg A; Dacic S; Galateau-Salle F; Hiroshima K; Hung YP; Klebe S; Krausz T; Khoor A; Litzky L; Marchevsky A; Nabeshima K; Nicholson AG; Pavlisko EN; Roden AC; Roggli V; Sauter JL; Schulte JJ; Sheaff M; Travis WD; Tsao MS; Walts AE; Colby TV
    Arch Pathol Lab Med; 2024 Apr; ():. PubMed ID: 38586983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.